Johnson & Johnson, ASCO 2025: Redefining global cancer care

At ASCO 2025, Johnson & Johnson contributed more than 70 abstracts, reflecting the depth of their oncology portfolio, and commitment to redefining what’s possible for a wide range of solid tumour and haematologic malignancies.

Onsite in Chicago, web editor Nicole Raleigh sat down with Mark Wildgust, vice president of global medical affairs, oncology, at Johnson & Johnson Innovative Medicine, to discuss J&J’s ambition to get in front of cancer on a global scale, and share with us more about that intention, some of the data presented, and highlights from the Congress as a whole.

Watch this and other conversations from ASCO 2025 here.